CD19 and congenital rubella syndrome: CD19-directed CAR T cells showed diverse results: while Axicabtagene ciloleucel (Axi-cel)-treatment did only show an association between peak expansion and neurological events but not CRS [5], a positive correlation of high-grade CRS with elevated CAR T cell expansion was reported for Tisa-cel [15].